Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Down 13.8% in March

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 1,620,000 shares, a decrease of 13.8% from the March 15th total of 1,880,000 shares. Currently, 2.0% of the company's shares are sold short. Based on an average daily trading volume, of 485,500 shares, the short-interest ratio is presently 3.3 days.

Compass Therapeutics Stock Up 1.3 %

NASDAQ CMPX traded up $0.02 on Friday, reaching $1.62. The company had a trading volume of 596,002 shares, compared to its average volume of 393,256. The stock has a market capitalization of $222.90 million, a P/E ratio of -4.76 and a beta of 0.78. The company's fifty day moving average is $1.83 and its 200 day moving average is $1.73. Compass Therapeutics has a 52-week low of $1.15 and a 52-week high of $3.62.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). On average, research analysts expect that Compass Therapeutics will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its stake in shares of Compass Therapeutics by 397.5% during the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company's stock worth $175,000 after acquiring an additional 52,865 shares during the period. BlackRock Inc. grew its stake in shares of Compass Therapeutics by 433.9% during the 3rd quarter. BlackRock Inc. now owns 872,497 shares of the company's stock worth $1,989,000 after acquiring an additional 709,071 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Compass Therapeutics during the 3rd quarter worth $55,000. Marshall Wace LLP grew its stake in shares of Compass Therapeutics by 118.4% during the 3rd quarter. Marshall Wace LLP now owns 51,816 shares of the company's stock worth $117,000 after acquiring an additional 28,089 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Compass Therapeutics by 58.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company's stock worth $5,428,000 after acquiring an additional 878,650 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CMPX has been the topic of a number of recent research reports. Wedbush reiterated an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a report on Friday, March 22nd. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Thursday, March 21st.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.